STATEN ISLAND, N.Y., July 1, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics ...
A total of 23 studies from 11 registries in eight countries spanning Europe, North America, and Oceania were identified and included in the review. Most studies were retrospective in nature and ...
Our scalable NLP system enabled us to generate real-world insights into NSCLC recurrences, paving the way for predictive models for preventing, diagnosing, and treating NSCLC recurrence. Our NLP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback